dc.contributor.author | ArdeshirRouhaniFard, S | |
dc.contributor.author | Dinh, PC | |
dc.contributor.author | Monahan, PO | |
dc.contributor.author | Fossa, SD | |
dc.contributor.author | Huddart, R | |
dc.contributor.author | Fung, C | |
dc.contributor.author | Song, Y | |
dc.contributor.author | Feldman, DR | |
dc.contributor.author | Hamilton, RJ | |
dc.contributor.author | Vaughn, DJ | |
dc.contributor.author | Martin, NE | |
dc.contributor.author | Kollmannsberger, C | |
dc.contributor.author | Einhorn, L | |
dc.contributor.author | Kroenke, K | |
dc.contributor.author | Travis, LB | |
dc.date.accessioned | 2021-07-02T11:37:09Z | |
dc.date.available | 2021-07-02T11:37:09Z | |
dc.date.issued | 2021-06-01 | |
dc.identifier.citation | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021, 30 (6), pp. 1129 - 1138 | |
dc.identifier.issn | 1055-9965 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4671 | |
dc.identifier.eissn | 1538-7755 | |
dc.identifier.doi | 10.1158/1055-9965.epi-20-1762 | |
dc.description.abstract | BACKGROUND: This study examined sociodemographic factors, cisplatin-related adverse health outcomes (AHO), and cumulative burden of morbidity (CBMPt) scores associated with medication use for anxiety and/or depression in testicular cancer survivors (TCS). METHODS: A total of 1,802 TCS who completed cisplatin-based chemotherapy ≥12 months previously completed questionnaires regarding sociodemographic features and cisplatin-related AHOs [hearing impairment, tinnitus, peripheral sensory neuropathy (PSN), and kidney disease]. A CBMPt score encompassed the number and severity of cisplatin-related AHOs. Multivariable logistic regression models assessed the relationship of individual AHOs and CBMPt with medication use for anxiety and/or depression. RESULTS: A total of 151 TCS (8.4%) used medications for anxiety and/or depression. No cisplatin-related AHOs were reported by 511 (28.4%) participants, whereas 622 (34.5%), 334 (18.5%), 287 (15.9%), and 48 (2.7%), respectively, had very low, low, medium, and high CBMPt scores. In the multivariable model, higher CBMPt scores were significantly associated with medication use for anxiety and/or depression (P < 0.0001). In addition, tinnitus (P = 0.0009), PSN (P = 0.02), and having health insurance (P = 0.05) were significantly associated with greater use of these medications, whereas being employed (P = 0.0005) and vigorous physical activity (P = 0.01) were significantly associated with diminished use. CONCLUSIONS: TCS with higher CBMPt scores had a higher probability of using medications for anxiety and/or depression, and conversely, those who were employed and physically active tended to have reduced use of these medications. IMPACT: Healthcare providers should encourage TCS to increase physical activity to improve both physical and mental health. Rehabilitation programs should assess work-related skills and provide career development counseling/training. | |
dc.format | Print-Electronic | |
dc.format.extent | 1129 - 1138 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER ASSOC CANCER RESEARCH | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.title | Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-04-06 | |
rioxxterms.version | AM | |
rioxxterms.versionofrecord | 10.1158/1055-9965.epi-20-1762 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology | |
pubs.issue | 6 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.publication-status | Published | |
pubs.volume | 30 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Academic Radiotherapy (Huddart) | |
icr.researchteam | Clinical Academic Radiotherapy (Huddart) | |
dc.contributor.icrauthor | Huddart, Robert | |